{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:55:18Z","timestamp":1784037318678,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2016YFC1100100"],"award-info":[{"award-number":["2016YFC1100100"]}]},{"name":"Major Research Plan of National Natural Science Foundation of China","award":["91649204"],"award-info":[{"award-number":["91649204"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To assess the efficacy and safety of interleukin (IL)-17A inhibitors in patients with ankylosing spondylitis (AS). PubMed, EMBASE, and Web of Science were searched up to 5 February 2020 for randomized controlled trials (RCTs) that assessed the efficacy and safety of IL-17A inhibitors in patients with AS. We used a meta-analytic approach to perform a random effects analysis or fixed effects analysis according to heterogeneity. Subgroup analyses between studies included medication, time to primary endpoint, and data source. Odds ratios (ORs) or mean differences (MDs) were used to assess the efficacy and safety of IL-17A inhibitors in AS. A total of ten RCTs with 2613 patients were eligible for inclusion in the analysis (six for secukinumab, two for ixekizumab, one for netakimab, and one for bimekizumab). Compared to placebo, IL-17A inhibitors improved ASAS20 response rate (OR\u2009=\u20092.58;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and ASAS40 response rate (OR\u2009=\u20092.80;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), and significantly increased the risk of AEs (OR\u2009=\u20091.23;<jats:italic>p<\/jats:italic>\u2009=\u20090.03) and nasopharyngitis (OR\u2009=\u20091.72;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), but not SAEs (OR\u2009=\u20090.87;<jats:italic>p<\/jats:italic>\u2009=\u20090.60). IL-17A inhibitors demonstrated better efficacy in patients with AS in several evaluation indicators. However, the safety of IL-17A inhibitors remains to be further studied in studies with larger sample size and longer follow-up times.<\/jats:p>","DOI":"10.1007\/s10067-020-05545-y","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T23:08:05Z","timestamp":1610492885000},"page":"3053-3065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Peng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengwu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"5545_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390:73\u201384","journal-title":"Lancet"},{"key":"5545_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379\u20131390","journal-title":"Lancet"},{"key":"5545_CR3","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127\u20132137","journal-title":"Lancet"},{"key":"5545_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A (2016) Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res 68:1320\u20131331","journal-title":"Arthritis Care Res"},{"key":"5545_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3233\/BMR-169657","volume":"31","author":"S Sag","year":"2018","unstructured":"Sag S, Nas K, Sag MS et al (2018) Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis. J Back Musculoskelet Rehabil 31:499\u2013505","journal-title":"J Back Musculoskelet Rehabil"},{"key":"5545_CR6","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00296-018-4124-z","volume":"38","author":"K Kruger","year":"2018","unstructured":"Kruger K, von Hinuber U, Meier F et al (2018) Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int 38:2121\u20132131","journal-title":"Rheumatol Int"},{"key":"5545_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/ard.20.3.215","volume":"20","author":"BJ de","year":"1961","unstructured":"de BJ, Polman A, De B-M (1961) Hereditary factors in rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 20:215\u2013220","journal-title":"Ann Rheum Dis"},{"key":"5545_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","volume":"1","author":"DA Brewerton","year":"1973","unstructured":"Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD (1973) Ankylosing spondylitis and HL-A 27. Lancet 1:904\u2013907","journal-title":"Lancet"},{"key":"5545_CR9","doi-asserted-by":"crossref","unstructured":"Dagfinrud, H., T.K. Kvien, and K.B. Hagen (2008) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev Cd002822","DOI":"10.1002\/14651858.CD002822.pub3"},{"key":"5545_CR10","doi-asserted-by":"crossref","unstructured":"Van Der Heijde, D., S. R Ramiro (2017) Annals of the Rheumatic Diseases 76:978\u2013991","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"5545_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DTY, Miller AS, Reveille JD, Caplan L (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 68:282\u2013298","journal-title":"Arthritis Rheumatol"},{"key":"5545_CR12","doi-asserted-by":"crossref","unstructured":"Bunte, K. and T. Beikler (2019) Th17 Cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci 20","DOI":"10.3390\/ijms20143394"},{"key":"5545_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E (2015) The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 11:415\u2013429","journal-title":"Nat Rev Rheumatol"},{"key":"5545_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","volume":"13","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE (2014) The IL-23\/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13:496\u2013502","journal-title":"Autoimmun Rev"},{"key":"5545_CR15","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","volume":"150","author":"E Rouvier","year":"1993","unstructured":"Rouvier E, Luciani MF, Mattei MG et al (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150:5445\u20135456","journal-title":"J Immunol"},{"key":"5545_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","volume":"14","author":"LS Taams","year":"2018","unstructured":"Taams LS, Steel KJA, Srenathan U, Burns LA, Kirkham BW (2018) IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol 14:453\u2013466","journal-title":"Nat Rev Rheumatol"},{"key":"5545_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9:556\u2013567","journal-title":"Nat Rev Immunol"},{"key":"5545_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s11926-014-0414-y","volume":"16","author":"M Frleta","year":"2014","unstructured":"Frleta M, Siebert S, McInnes IB (2014) The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep 16:414","journal-title":"Curr Rheumatol Rep"},{"key":"5545_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20110496","volume":"122","author":"S Zhu","year":"2012","unstructured":"Zhu S, Qian Y (2012) IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 122:487\u2013511","journal-title":"Clin Sci (Lond)"},{"key":"5545_CR20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60:1647\u20131656","journal-title":"Arthritis Rheum"},{"key":"5545_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling D, Cedoz JP, Racadot E, Dumoulin G (2007) Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74:304\u2013305","journal-title":"Joint Bone Spine"},{"key":"5545_CR22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/art.23655","volume":"58","author":"C Jandus","year":"2008","unstructured":"Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58:2307\u20132317","journal-title":"Arthritis Rheum"},{"key":"5545_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3899\/jrheum.110862","volume":"39","author":"L Limon-Camacho","year":"2012","unstructured":"Limon-Camacho L, Vargas-Rojas MI, Vazquez-Mellado J et al (2012) In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis. J Rheumatol 39:830\u2013835","journal-title":"J Rheumatol"},{"key":"5545_CR24","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, Weedon H, Street S, Thomas R, Thomas GP, Brown MA (2012) Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum 64:1420\u20131429","journal-title":"Arthritis Rheum"},{"key":"5545_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","volume":"30","author":"Y Mei","year":"2011","unstructured":"Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye D (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30:269\u2013273","journal-title":"Clin Rheumatol"},{"key":"5545_CR26","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13:R95","journal-title":"Arthritis Res Ther"},{"key":"5545_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/1744666X.2019.1561281","volume":"15","author":"S Dubash","year":"2019","unstructured":"Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H (2019) The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol 15:123\u2013134","journal-title":"Expert Rev Clin Immunol"},{"key":"5545_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366:1190\u20131199","journal-title":"N Engl J Med"},{"key":"5545_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72:863\u2013869","journal-title":"Ann Rheum Dis"},{"key":"5545_CR30","doi-asserted-by":"crossref","unstructured":"Hueber, W., D.D. Patel, T. Dryja, et al (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72","DOI":"10.1126\/scitranslmed.3001107"},{"key":"5545_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, Li D, Russell C, Newmark R, Zhang N, Chon Y, Hsu YH, Lin SL, Klekotka P (2016) A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol 111:1599\u20131607","journal-title":"Am J Gastroenterol"},{"key":"5545_CR32","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landew\u00e9 R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705\u20131713","journal-title":"Lancet"},{"key":"5545_CR33","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B (2016) Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis a phase III randomized trial (MEASURE 1). Arthritis & Rheumatology 68:2901\u20132910","journal-title":"Arthritis & Rheumatology"},{"key":"5545_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, J\u00e4rvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, COAST-W Study Group (2019) Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis and Rheumatology 71:599\u2013611","journal-title":"Arthritis and Rheumatology"},{"key":"5545_CR35","unstructured":"Erdes S, Nasonov E, Kunder E et al (2019) Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol"},{"key":"5545_CR36","doi-asserted-by":"crossref","unstructured":"Huang, F., F. Sun, W. Wan, et al (2019) Secukinumab provides rapid and significant improvement in the signs and symptoms of ankylosing spondylitis: primary (16-week) results from a phase 3 China-centric study, measure 5. Annals of the Rheumatic Diseases 78 (Supplement 2):894-895","DOI":"10.1136\/annrheumdis-2019-eular.2560"},{"key":"5545_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, Richards HB, Porter B (2018) Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatology and Therapy 5:447\u2013462","journal-title":"Rheumatology and Therapy"},{"key":"5545_CR38","doi-asserted-by":"crossref","unstructured":"Pavelka, K., A. Kivitz, E. Dokoupilova, et al (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Research and Therapy 19 (1) (no pagination)","DOI":"10.1186\/s13075-017-1490-y"},{"key":"5545_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB, MEASURE 2 Study Group (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 study. Ann Rheum Dis 76:571\u2013575","journal-title":"Ann Rheum Dis"},{"key":"5545_CR40","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, van den Bosch F, Sieper J, Tomita T, Landew\u00e9 R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H, COAST-V study group (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392:2441\u20132451","journal-title":"Lancet"},{"key":"5545_CR41","doi-asserted-by":"crossref","unstructured":"Van Der Heijde, D., L.S. Gensler, A. Deodhar, et al (2019) Dual neutralisation of IL-17A and IL-17F with bimekizumab was associated with improvements in patient-reported and quality-of-life outcomes in patients with active ankylosing spondylitis: results from a phase 2B, randomised, double-blind, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases 78 (Supplement 2):193","DOI":"10.1136\/annrheumdis-2019-eular.6607"},{"key":"5545_CR42","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s10067-017-3693-7","volume":"36","author":"P Ungprasert","year":"2017","unstructured":"Ungprasert P, Erwin PJ, Koster MJ (2017) Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol 36:1569\u20131577","journal-title":"Clin Rheumatol"},{"key":"5545_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003060","volume":"95","author":"C Chen","year":"2016","unstructured":"Chen C, Zhang X, Xiao L, Zhang XS, Ma XL (2016) Comparative effectiveness of biologic therapy regimens for ankylosing spondylitis: a systematic review and a network meta-analysis. Medicine (Baltimore) 95:e3060","journal-title":"Medicine (Baltimore)"},{"key":"5545_CR44","doi-asserted-by":"crossref","unstructured":"Cumpston, M., T. Li, M.J. Page, et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:Ed000142","DOI":"10.1002\/14651858.ED000142"},{"key":"5545_CR45","first-page":"50","volume":"36","author":"X Baraliakos","year":"2018","unstructured":"Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B, MEASURE 1 Study Group (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36:50\u201355","journal-title":"Clin Exp Rheumatol"},{"key":"5545_CR46","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford) 58:859\u2013868","journal-title":"Rheumatology (Oxford)"},{"key":"5545_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5:e001005","journal-title":"RMD Open"},{"key":"5545_CR48","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, MEASURE 1 study group (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76:1070\u20131077","journal-title":"Ann Rheum Dis"},{"key":"5545_CR49","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis 75:408\u2013412","journal-title":"Ann Rheum Dis"},{"key":"5545_CR50","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/acr.23233","volume":"69","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, on behalf of the Measure 2 Study Group (2017) Secukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III study. Arthritis Care Res (Hoboken) 69:1020\u20131029","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5545_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open 3:e000592","journal-title":"RMD Open"},{"key":"5545_CR52","doi-asserted-by":"crossref","unstructured":"Dougados, M., J.C. Wei, R. Landewe, et al (2019) Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis","DOI":"10.1136\/annrheumdis-2019-216118"},{"key":"5545_CR53","doi-asserted-by":"crossref","unstructured":"Erichsen, C.Y., P. Jensen, and K. Kofoed (2019) Biologic therapies targeting the interleukin (IL)-23\/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.15879"},{"key":"5545_CR54","doi-asserted-by":"crossref","unstructured":"Loft, N.D., S. Vaengebjerg, A.S. Halling, et al (2019) Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.16073"},{"key":"5545_CR55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00296-016-3480-9","volume":"36","author":"S Kunwar","year":"2016","unstructured":"Kunwar S, Dahal K, Sharma S (2016) Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatol Int 36:1065\u20131075","journal-title":"Rheumatol Int"},{"key":"5545_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CEOR.S192235","volume":"11","author":"T Purmonen","year":"2019","unstructured":"Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J (2019) Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res 11:159\u2013168","journal-title":"Clinicoecon Outcomes Res"},{"key":"5545_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/13696998.2018.1539400","volume":"22","author":"R Goeree","year":"2019","unstructured":"Goeree R, Chiva-Razavi S, Gunda P, Jain M, Jugl SM (2019) Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. J Med Econ 22:45\u201352","journal-title":"J Med Econ"},{"key":"5545_CR58","unstructured":"Citera, G., P.M. Bianculli, A. Khare, et al (2018) Cost-effectiveness of secukinumab versus other biologics in the treatment ofankylosing spondylitis: an Argentinean perspective. Journal of Clinical Rheumatology 24 (3 Supplement 1):S117"},{"key":"5545_CR59","doi-asserted-by":"crossref","unstructured":"Marzo-Ortega, H., A. Halliday, S. Jugl, et al (2017) The cost-effectiveness of secukinumab versus tumour necrosis factor a inhibitor biosimilars for ankylosing spondylitis in the UK. Rheumatology (United Kingdom) 56 (Supplement 2):ii92","DOI":"10.1093\/rheumatology\/kex062.108"},{"issue":"7","key":"5545_CR60","doi-asserted-by":"publisher","first-page":"A539","DOI":"10.1016\/j.jval.2016.09.1117","volume":"19","author":"D Fedyaev","year":"2016","unstructured":"Fedyaev D, Derkach EV (2016) Cost-effectiveness analysis of different biologic agents for ankylosing spondylitis treatment in Russia. Value Health 19(7):A539","journal-title":"Value Health"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05545-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05545-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05545-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T12:44:36Z","timestamp":1697546676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05545-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5545"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05545-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}